Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Stock Information for Xenetic Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Xenetic Biosciences Inc.

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.